Determination of the ideal concentration of BVL-GSK098 required to boost ETH activity Institute of Tropical Medicine
BioVersys AG, Hochbergerstrasse 60c, 4057 Basel, Switzerland, Department of Biomedical Sciences, Management, Mycobacteriology
BioVersys’ Clinical Candidate BVL-GSK098 is a small molecule able to inhibit Mycobacterium tuberculosis transcription regulator, VirS. By doing so, BVL-GSK098 has been shown to boost bioactivation of ethionamide (ETH) and, consequently, to lower ETH MIC. In addition, since resistance to ETH is due to mutations in EthA, the enzyme responsible for ETH bioactivation, the presence of BVL-GSK098, which activates an EthA-independent - VirS-dependent ...